Effect of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases: Post hoc analyses of three randomized, placebo-controlled trials.
Hum Vaccin ImmunotherMay 5, 2026 (epub)
Faye Yu, Eugene Myshkin, Brandon Nguyen et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the effects of nipocalimab on IgG responses to vaccinations and viral infections in patients with IgG autoantibody-mediated diseases, using post hoc analyses from three randomized, placebo-controlled trials. The results indicated that nipocalimab did not impair IgG responses, with 73.3% of participants maintaining anti-HZV levels and 76.5% maintaining anti-TT levels throughout treatment.
Key findings
- Nipocalimab treatment resulted in a 60%-65% reduction in pre-existing anti-TT IgG levels.
- 73.3% of nipocalimab-treated participants maintained anti-HZV IgG levels above the reference threshold.
- Participants treated with nipocalimab had similar IgG responses to TT and SARS-CoV-2 vaccinations as those receiving placebo.
- SARS-CoV-2 infections in the study were mild to moderate with no complications.
Why it matters
Understanding the impact of treatments like nipocalimab on vaccine responses is crucial for managing patients with IgG autoantibody-mediated diseases, ensuring they maintain adequate immunity while receiving therapy.